Subspecialties Oncology, Genetics and epigenetics, Biochemistry and molecular biology, Technology and innovation

Validating a targeted NGS approach for molecular characterization of gliomas

10/01/2020

sponsored by QIAGEN

Targeted NGS has been instrumental in driving our understanding of disease, mainly because it reduces costs per sample, enables the detection of low frequency variants and allows for content customization. Manually designing targeted NGS panels is time- and resource- consuming, but QIAGEN’s primer design algorithms streamline and simplify the process, to deliver the highest possible design coverage. A case study on custom DNA glioma panels will be discussed for clinical research applications in order to molecular classify glioblastomas and the stem cells isolated in 4 molecular subclasses following validation in a clinical research setting to improve results in the molecular definition of gliomas according to WHO classification.

Learning Objectives

How to approach customer panel design entering your own content, such as genes or genomic coordinates
Elements required to overcome challenges of tumor profiling
Validating a custom DNA panel from research to molecular definition of gliomas

Available On-Demand

Visit our Webinar Hub

Email*

Choose a password

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the Infectious Diseases field I want to stay up to date with the Pathologist Educator field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.